Adaptimmune Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Share-based compensation

Share-based compensation

3 Months Ended

Mar. 31, 2025

Note 11 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended
		March 31,
	2025		2024
Research and development	$	(132)	$	813
Selling, general and administrative		801		2,289
	$	669	$	3,102

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended
		March 31,
	2025		2024
Number of options over ordinary shares granted		24,711,600		37,097,688
Weighted average fair value of ordinary shares options	$	0.07	$	0.12
Number of additional options with a nominal exercise price granted		24,944,376		26,984,352
Weighted average fair value of options with a nominal exercise price	$	0.10	$	0.14